DISABILITY NETWORK SOUTHWEST MICHIGAN

COVID-19 PREPAREDNESS AND RESPONSE PLAN

Updated July 7, 2021

Table of Contents

DISABILITY NETWORK SOUTHWEST MICHIGAN

COVID-19 PREPAREDNESS AND RESPONSE PLAN

Disability Network Southwest Michigan takes the health and safety of our employees seriously. We are committed to reducing the risk of exposure to COVID-19 and to providing a healthy and safe workplace for our employees.

This Plan is based on information and guidance from the CDC and OSHA at the time of its development, and is subject to change based on further information provided by the CDC, OSHA, and other public officials. Disability Network may also amend this Plan based on operational needs. This plan will be made available to employees via agency email and will be made available to customers (on our website, via social media, upon request, etc). This plan pertains to all Disability Network staff and worksites, where applicable.

Disability Network has identified the following potential sources to spread COVID-19 in the workplace:

- Co-workers
- Customers/Community Partners
- Vendors, visitors and the general public

Employees fall into the Lower or Medium exposure risk as described by the categories below:

- Lower exposure risk (the work performed does not require direct contact with people known or suspected to be infected with COVID-19 or frequent close contact with the public).

- Medium exposure risk (the work performed requires frequent and/or close contact with people who may be infected with COVID-19 but who are not known COVID-19 patients, or contact with the general public in areas where there is ongoing community transmission).

- High exposure risk (healthcare delivery and support staff exposed to known or suspected COVID-19 patients; medical transport workers moving known or suspected COVID-19 patients in enclosed vehicles; mortuary workers involved in preparing the bodies of people who are known to have, or suspected of having, COVID-19 at the time of their death.

ENGINEERING CONTROLS & AIR QUALITY IMPROVEMENTS

On April 5, 2021, TowerPinkster conducted a Building Readiness inspection and assessment at 517 E Crosstown Parkway. The following recommendations have been, or will be, completed in order to improve the air quality of the Kalamazoo office.

1. Provide ventilation air to each furnace (completed July 2021)

2. Increase outdoor ventilation by running the fans on each unit continuously (programmable thermostats have been installed that allow fans to run continuously, beginning 2 hours before staff and customers arrive and continuing 2 hours after the building empties)
3. Develop a routine to turn on all portable air purifiers (completed) and the exhaust fan in the kitchen (completed)

In the Community Building, Battle Creek office and St. Joseph office, staff should consistently use the office air purifiers in order to ensure air quality and open doors and windows whenever possible.

Definitions- the following definitions will be used throughout the plan:

- "close contact" is defined as someone who was within 6 feet for a total of 15 minutes or more within 2 days prior to illness onset, regardless of whether the contact was wearing a mask.
- "fully vaccinated persons" means persons for whom at least 2 weeks have passed since receiving the final dose of an FDA-approved or authorized COVID-19 vaccine.
- "suspected cases of COVID-19" means persons who have symptoms of COVID-19 but have not been confirmed through diagnostic testing.
- "known cases of COVID-19" means persons who have been confirmed through diagnostic testing.

RESPONSIBILITIES OF SUPERVISORS AND MANAGERS

All managers and supervisors must be familiar with this Plan and be ready to answer questions from employees. Managers and supervisors must set a good example by following this Plan at all times. This involves practicing good personal hygiene and on the job safety practices to prevent the spread of the virus. Managers and supervisors must encourage this same behavior from all employees.

RESPONSIBILITIES OF EMPLOYEES

Disability Network is asking every one of our employees to help with our prevention efforts while at work. In order to minimize the impact of COVID-19 at our worksite, everyone must play their part. It's all about personal protection. Please keep yourself safe. As set forth below, Disability Network has instituted various housekeeping, social distancing, and other best practices at our workplace to minimize exposure to COVID-19 and prevent its spread. All employees must follow these best practices at all times for them to be effective. Beyond these best practices, Disability Network requires employees to report immediately to their supervisor if they are experiencing signs or symptoms of COVID-19, as described below. If employees have a specific question about this Plan or COVID-19, they should ask their supervisor for information. If employees would like to report a hazardous work environment, they should contact the President & CEO at 269-345-1516, ext. 105 or cooperj@dnswm.org.

OSHA and the CDC have provided the following control and preventative guidance for all workers, regardless of exposure risk:

- Frequently wash your hands with soap and water for at least 20 seconds. When soap and running water are unavailable, use an alcohol-based hand sanitizer with at least 60% alcohol.
- Avoid touching your eyes, nose, or mouth with unwashed hands.
- Follow appropriate respiratory etiquette, which includes covering your mouth and nose with a tissue for coughs and sneezes. Do not use your hand to cover your cough. You can also cough into your elbow.
- Avoid close contact with people who are sick.
- If an employee is sick, they are not permitted to work in any of Disability Network's three buildings or in the community representing Disability Network.
- Employees who are not fully vaccinated must maintain appropriate social distance of six feet to the greatest extent possible.
- It is highly recommended that employees who are not fully vaccinated wear a face covering when interacting with staff, visitors or customers or when traveling throughout the building or in common areas.

In addition, employees must familiarize themselves with the symptoms and exposure risks of COVID-19. The primary symptoms of COVID-19 include the following and can appear 2-14 days after exposure and range from mild to severe illness:

- Cough
- Shortness of breath or difficulty breathing
- Fever
- Chills
- Repeated shaking with chills
- Muscle pain
- Headache
- Sore throat
- New loss of taste or smell
- Vomiting
- Diarrhea
- Other respiratory problems

If an employee develops a fever over 100.4 degrees Fahrenheit and symptoms of respiratory illness, such as an atypical cough or shortness of breath, they must not report to work (either onsite or in the general public) and should notify their supervisor immediately and consult their healthcare provider. Other concerning symptoms such as cough, shortness of breath or difficulty breathing, chills, body aches or muscle pain, sore throat, headache, diarrhea, nausea/vomiting and new loss of smell or taste should encourage employees to refrain from working onsite, with customers, or the general public.

If an employee develops the symptoms described above while at work, the employee will immediately initiate separation from other employees, customers, and the general public and notify their supervisor. Employees with these symptoms will be requested to leave work. If the employee is unable to immediately leave the workplace, they will isolate in an appropriate area. In the Kalamazoo office, Conference Room A will serve as an isolation area.

If employees come into close contact (either at work or outside of work) with someone showing these symptoms, they must notify their supervisor immediately.

Employees with a known or confirmed case of COVID-19 will be allowed to return to the workplace only after they are no longer infectious according to the latest guidelines from the CDC and they are released from any quarantine or isolation order by the local public health department.

WORKSITE PREVENTATIVE MEASURES

Minimizing exposure from co-workers. Disability Network will take the following steps to minimize exposure from co-workers to COVID-19.

Current Phase – Phase 3.5 -

- Educate employees on protective behaviors that reduce the spread of COVID-19 and provide employees with the necessary tools for these protective behaviors, including:
    - Posting CDC or other state or local information, including recommendations on risk factors.
    - Providing tissues and no-touch garbage cans to minimize exposure to infectious secretions.
    - Inform employees of the importance of good hand hygiene. Regularly washing hands with soap and water for at least 20 seconds is one of the most effective ways for employees to minimize exposure to COVID-19. If soap and water are not readily available, employees should use alcohol-based hand sanitizer that is at least 60% alcohol. If hands are visibly dirty, soap and water should be chosen over hand sanitizer.
    - Encourage good hand hygiene by ensuring that adequate supplies of soap and hand sanitizer are maintained and placing hand sanitizers in multiple locations.
    - Not allow handshaking and instead encourage the use of other non-contact methods of greeting.
    - Require social distancing (6 ft) to the greatest extent possible while in the workplace for all unvaccinated employees.
    - Provide masks to all employees. It is highly recommended that unvaccinated staff wear a face covering when interacting with staff, customers and the general public.

- Fully vaccinated employees may ride share with other vaccinated staff without wearing a mask. Unvaccinated staff may not ride share and must wear a mask if using public transit, train or airplane for work related travel.
- On August 2, 2021, vaccinated staff may transport customers and volunteers as is detailed in Policy 167. Unvaccinated staff may not transport customers and volunteers.
- Remote work from home must be approved by the employee's supervisor.

- Restrict employees from the workplace if they display symptoms of COVID-19.
- Sick employees or employees who have been in close contact with a confirmed or suspected case of COVID-19must contact their supervisor to determine possible quarantining or remote work options.
- If an employee has a confirmed case of COVID-19 (Coronavirus), the CEO or designee will implement the following protocol;*
  - Within 24 hours, notify the local public health department and coworkers, suppliers, and contractors who may have come in contact with the employee (maintain confidentiality of the employee's identity whenever possible);
  - Maintain a record of all confirmed employee cases and the resulting notification to public health and to those potentially exposed to the employee;
  - Follow CDC recommended cleaning and disinfecting in all affected areas.
- In the case that an employee has a confirmed case of COVID-19, the CDC's cleaning and disinfecting guidelines will be followed:
  - Less than 24 hours since the employee has been in the building –
    - Clean and disinfect the space. If more than 24 hours since the employee has been in the building, cleaning is sufficient.
  - If more than 3 days have passed since the employee has been in the building, no cleaning is required.
- Perform increased routine environmental cleaning and disinfection in high-touch areas, for instance, doors, copy room using a disinfectant product that is effective against COVID-19.

Minimizing exposure from customers and community partners.
Disability Network will post appropriate local, state, or CDC available posters and information in customer accessed areas. Disability Network will implement the following steps to minimize exposure from customers and community partners to COVID-19:

- Face-to-face interactions with customers will be allowed:
  - As of July 7, 2021, meetings must be scheduled in advance. Beginning on Tuesday August 3, 2021, walk-in customers will be welcomed in the Kalamazoo office on Tuesdays and Thursdays from 9 am – 4 pm.
  - It is highly recommended for unvaccinated staff and customers/guests to wear a face covering when meeting with customers/guests. Vaccinated and unvaccinated staff must ask each customer/guest their preference for face coverings before the meeting begins; options are 1. Both staff and customer wear a face covering 2. Staff wears a face covering 3. Customer wears a face covering 4. Neither wear a face covering.

- There must be 6 foot of space, or more if possible, between unvaccinated staff and customers/guests at all times.
- Meetings can occur in Conference Room A, the computer lab or individual offices.
- Customers will not have access to the computer lab expect for meetings with staff members.
- In the event that a customer has a confirmed case of COVID-19 that we know about, the CDC's cleaning and disinfecting guidelines will be followed:
    - Less than 24 hours since the customer has been in the building – Clean and disinfect the space.
    - If more than 24 hours since the customer has been in the building, cleaning is sufficient.
    - If more than 3 days have passed since the employee has been in the building, no cleaning is required.

- Community Education activities will be provided using Zoom or other online platforms or in settings that are approved by the Advocacy & Community Education Program Manager through Fiscal Year 2021. On October 1, 2021, workshops and presentations can return to in person, if appropriate.
- As of August 2, 2021, support groups and advocacy groups will be allowed to meet in person. It is highly recommended that unvaccinated staff and customers/guests wear a face covering.
- Staff can attend community meetings as long as workplace and/or host guidelines are followed. For instance, if an agency is hosting the meeting and they require all guests to wear masks, the staff member should wear their mask.

Battle Creek Site –
Staff who work out of the Battle Creek office will follow the above guidelines when applicable. Specific guidelines meant for the Battle Creek site are as follows:

St. Joseph Site –
Staff who work out of the St. Joseph office will follow the above guidelines when applicable. Specific guidelines meant for the St. Joseph site are as follows:

- AAA rules will be followed by staff that equal or exceed requirements in place by Disability Network for worksite preventative measures.

Disability Network Southwest Michigan
COVID-19 Voluntary Vaccination Policy
2-5-2021

In accordance with Disability Network Southwest Michigan's duty to provide and maintain a workplace that is free of known hazards, we are adopting a COVID-19 vaccine voluntary policy to safeguard the health of our employees and their families; our customers and visitors; and the community at large from the infectious COVID-19 disease, that may be reduced by vaccinations. This policy will comply with all applicable laws and is based on guidance from the Centers for Disease Control and Prevention and local health authorities, as applicable.

COVID-19 vaccines are often administered with no out of pocket costs to individuals. If employees cannot receive a free vaccine and desire a vaccine, they are to utilize health care coverage to cover a vaccine's expense. If an employee is not covered by a health care policy or their health care policy does not cover any portion of the cost to receive a COVID-19 vaccine, the employee may request reimbursement of up to $150 to cover their out-of-pocket costs for the vaccine and vaccine administration. If an employee receives a COVID-19 vaccine that is a two-part series, like the Pfizer and Moderna COVID-19 vaccines, they may submit for reimbursement after they are billed for each of the two vaccines in the series. Employer-paid reimbursement for both vaccines in a series, cumulatively, is up to $150 total. Employees who have health care coverage are to provide a copy of the bill they are responsible for, or Explanation of Benefits (EOB) after the health care coverage has approved the portion of the bill that will be covered by health care insurance. Employees are to submit documentation as soon as possible to the finance director for reimbursement for COVID-19 vaccine out-of-pocket costs within 120 days after receiving a COVID-19 vaccine. If an employee receives a two-part vaccine series, they have within 120 days of receipt of the initial vaccine in the series to request reimbursement. Employees will be reimbursed directly and are responsible for paying the medical bill(s) specific to COVID-19 vaccines.

Employees who receive a COVID-19 vaccine may request mileage reimbursement of up to 200 total miles to cover the mileage to and from the site where they receive a vaccine. Mileage reimbursement is to be calculated to and from an employee's assigned office (Our current status of assigned office during COVID-19 Preparedness and Response Plan is the employee’s home). Mileage reimbursement may be requested for a vaccine received any day of the week, including on a Saturday or Sunday.

Employees who receive a COVID-19 vaccine on a day of the week that they are typically scheduled to work are eligible to receive up to the number of hours of pay that they would typically receive on that day of the week, regardless of the number of hours of work they perform. An employee who has a schedule of working 40 hours per week with a typical schedule of eight (8) hours of work per day would be eligible for up to eight (8) hours of pay on the weekday that they receive a vaccine. Time spent traveling to and from the site where the vaccine is administered and time spent at the vaccination site is to be listed as office work in Net-CIL, as receiving a COVID-19 vaccine is considered a work activity. Staff is encouraged not to list personal medical information in the notes section of Net-CIL work logs.

For any hours on the workday that a person receives a vaccine that they are not engaged in work activity, related to experiencing symptoms from the vaccine, they are to submit a request to their supervisor for paid time off and list the number of paid time off hours in the PTO column of their PAR. When the supervisor submits a PTO request to the Finance Director, they must note that the PTO is connected to receipt of a COVID-19 vaccine. The PTO hours will not be deducted from a person's PTO balance.

Employees who receive a COVID-19 vaccine on a day of the week that they are typically not scheduled to work are eligible for paid work time to travel to and from the vaccination site and time spent at the vaccination site. Employees who are scheduled to receive a vaccine on a day of the week that they typically are not scheduled to work are to discuss with a supervisor how they can modify their schedule during the week when the vaccine is scheduled to try to reduce the likelihood of entering into overtime pay. If a non-exempt employee's schedule is unable to be modified, overtime pay for work over 40 hours per week will occur, with prior approval by supervisor.

In the event that an employee travels to a vaccine administration site where they are scheduled to receive a vaccine and learns that the vaccine is unavailable, the employee will still be eligible to submit for mileage reimbursement and count the time traveling to and from the vaccine administration site and time at the vaccine administration site as paid work time.

Employees who receive a COVID-19 vaccine and experience symptoms where time off from work would help manage the symptoms are eligible for up to eight (8 hours) of pay on the business day following the day they receive a COVID-19 vaccine. In the event a person receives a vaccine on a Friday, Saturday, or Sunday, the employee will be eligible to request paid work hours on the following Monday, should they experience symptoms where time off from work would help manage symptoms. Employees requesting time off the business day following receipt of a vaccine are to submit a request to their supervisor for paid time off and list the number of paid time off hours in the PTO column of their PAR. When the supervisor submits a PTO request to the Finance Director, they must note that the PTO is connected to managing symptoms on the business day following receipt of a COVID-19 vaccine. The PTO hours will not be deducted from a person's PTO balance.

All employees who receive a COVID-19 vaccine are to provide documentation to the HR Director that they have received a COVID-19 vaccine within 14 calendar days of receipt of a vaccine. The documentation should list the date that the vaccine was administered and the entity that administered the vaccine. If an employee receives a vaccine that requires two doses for efficacy, documentation should be provided to the HR Director for each of the vaccine doses received. This documentation will be stored separately from an employee's personnel file in a separate locked file drawer from where an employee's personnel file is stored.

Information about the Emergency Use Authorization (EUA) for the Pfizer-Biontech COVID-19 vaccine and Moderna COVID-19 vaccine are listed below. These fact sheets can be viewed online at the U.S. Food and Drug Administration website of www.fda.gov.

FACT SHEET FOR RECIPIENTS AND CAREGIVERS

EMERGENCY USE AUTHORIZATION (EUA) OF THE PFIZER-BIONTECH COVID-19 VACCINE TO PREVENT CORONAVIRUS DISEASE 2019 (COVID-19) IN INDIVIDUALS 16 YEARS OF AGE AND OLDER

You are being offered the Pfizer-BioNTech COVID-19 Vaccine to prevent Coronavirus Disease 2019 (COVID-19) caused by SARS-CoV-2. This Fact Sheet contains information to help you understand the risks and benefits of the Pfizer-BioNTech COVID-19 Vaccine, which you may receive because there is currently a pandemic of COVID-19.

The Pfizer-BioNTech COVID-19 Vaccine is a vaccine and may prevent you from getting COVID-19. There is no U.S. Food and Drug Administration (FDA) approved vaccine to prevent COVID-19.

Read this Fact Sheet for information about the Pfizer-BioNTech COVID-19 Vaccine. Talk to the vaccination provider if you have questions. It is your choice to receive the Pfizer-BioNTech COVID-19 Vaccine.

The Pfizer-BioNTech COVID-19 Vaccine is administered as a 2-dose series, 3 weeks apart, into the muscle.

The Pfizer-BioNTech COVID-19 Vaccine may not protect everyone.

This Fact Sheet may have been updated. For the most recent Fact Sheet, please see www.cvdvaccine.com.

WHAT YOU NEED TO KNOW BEFORE YOU GET THIS VACCINE

WHAT IS COVID-19?

COVID-19 disease is caused by a coronavirus called SARS-CoV-2. This type of coronavirus has not been seen before. You can get COVID-19 through contact with another person who has the virus. It is predominantly a respiratory illness that can affect other organs. People with COVID-19 have had a wide range of symptoms reported, ranging from mild symptoms to severe illness. Symptoms may appear 2 to 14 days after exposure to the virus. Symptoms may include: fever or chills; cough; shortness of breath; fatigue; muscle or body aches; headache; new loss of taste or smell; sore throat; congestion or runny nose; nausea or vomiting; diarrhea.

WHAT IS THE PFIZER-BIONTECH COVID-19 VACCINE?

The Pfizer-BioNTech COVID-19 Vaccine is an unapproved vaccine that may prevent COVID-19. There is no FDA-approved vaccine to prevent COVID-19.

The FDA has authorized the emergency use of the Pfizer-BioNTech COVID-19 Vaccine to prevent COVID-19 in individuals 16 years of age and older under an Emergency Use Authorization (EUA).

For more information on EUA, see the "**What is an Emergency Use Authorization (EUA)?**" section at the end of this Fact Sheet.

WHAT SHOULD YOU MENTION TO YOUR VACCINATION PROVIDER BEFORE YOU GET THE PFIZER-BIONTECH COVID-19 VACCINE?

Tell the vaccination provider about all of your medical conditions, including if you:

- have any allergies
- have a fever
- have a bleeding disorder or are on a blood thinner
- are immunocompromised or are on a medicine that affects your immune system
- are pregnant or plan to become pregnant
- are breastfeeding
- have received another COVID-19 vaccine

WHO SHOULD GET THE PFIZER-BIONTECH COVID-19 VACCINE?

FDA has authorized the emergency use of the Pfizer-BioNTech COVID-19 Vaccine in individuals 16 years of age and older.

WHO SHOULD <u>NOT</u> GET THE PFIZER-BIONTECH COVID-19 VACCINE?

You should not get the Pfizer-BioNTech COVID-19 Vaccine if you:

- had a severe allergic reaction after a previous dose of this vaccine
- had a severe allergic reaction to any ingredient of this vaccine.

WHAT ARE THE INGREDIENTS IN THE PFIZER-BIONTECH COVID-19 VACCINE?

The Pfizer-BioNTech COVID-19 Vaccine includes the following ingredients: mRNA, lipids ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate), 2 [(polyethylene glycol)-2000]-N,N-ditetradecylacetamide, 1,2-Distearoyl-sn-glycero-3-phosphocholine, and cholesterol), potassium chloride, monobasic potassium phosphate, sodium chloride, dibasic sodium phosphate dihydrate, and sucrose.

HOW IS THE PFIZER-BIONTECH COVID-19 VACCINE GIVEN?

The Pfizer-BioNTech COVID-19 Vaccine will be given to you as an injection into the muscle.

The Pfizer-BioNTech COVID-19 Vaccine vaccination series is 2 doses given 3 weeks apart.

If you receive one dose of the Pfizer-BioNTech COVID-19 Vaccine, you should receive a second dose of this same vaccine 3 weeks later to complete the vaccination series.

Revised: December 2020

HAS THE PFIZER-BIONTECH COVID-19 VACCINE BEEN USED BEFORE?
The Pfizer-BioNTech COVID-19 Vaccine is an unapproved vaccine. In clinical trials, approximately 20,000 individuals 16 years of age and older have received at least 1 dose of the Pfizer-BioNTech COVID-19 Vaccine.

WHAT ARE THE BENEFITS OF THE PFIZER-BIONTECH COVID-19 VACCINE?
In an ongoing clinical trial, the Pfizer-BioNTech COVID-19 Vaccine has been shown to prevent COVID-19 following 2 doses given 3 weeks apart. The duration of protection against COVID-19 is currently unknown.

WHAT ARE THE RISKS OF THE PFIZER-BIONTECH COVID-19 VACCINE?
Side effects that have been reported with the Pfizer-BioNTech COVID-19 Vaccine include:

- injection site pain
- tiredness
- headache
- muscle pain
- chills
- joint pain
- fever
- injection site swelling
- injection site redness
- nausea
- feeling unwell
- swollen lymph nodes (lymphadenopathy)

There is a remote chance that the Pfizer-BioNTech COVID-19 Vaccine could cause a severe allergic reaction. A severe allergic reaction would usually occur within a few minutes to one hour after getting a dose of the Pfizer-BioNTech COVID-19 Vaccine. For this reason, your vaccination provider may ask you to stay at the place where you received your vaccine for monitoring after vaccination. Signs of a severe allergic reaction can include:

- Difficulty breathing
- Swelling of your face and throat
- A fast heartbeat
- A bad rash all over your body
- Dizziness and weakness

These may not be all the possible side effects of the Pfizer-BioNTech COVID-19 Vaccine. Serious and unexpected side effects may occur. Pfizer-BioNTech COVID-19 Vaccine is still being studied in clinical trials.

WHAT SHOULD I DO ABOUT SIDE EFFECTS?
If you experience a severe allergic reaction, call 9-1-1, or go to the nearest hospital.

Revised: December 2020

Call the vaccination provider or your healthcare provider if you have any side effects that bother you or do not go away.

Complete and submit reports to VAERS online at https://vaers.hhs.gov/reportevent.html. For further assistance with reporting to VAERS call 1-800-822-7967. Please include "Pfizer-BioNTech COVID-19 Vaccine EUA" in the first line of box #18 of the report form.

In addition, you can report side effects to Pfizer Inc. at the contact information provided below.

Website	Fax number	Telephone number
www.pfizersafetyreporting.com	1-866-635-8337	1-800-438-1985

You may also be given an option to enroll in v-safe. V-safe is a new voluntary smartphone-based tool that uses text messaging and web surveys to check in with people who have been vaccinated to identify potential side effects after COVID-19 vaccination. V-safe asks questions that help CDC monitor the safety of COVID-19 vaccines. V-safe also provides second-dose reminders if needed and live telephone follow-up by CDC if participants report a significant health impact following COVID-19 vaccination. For more information on how to sign up, visit: www.cdc.gov/vsafe.

WHAT IF I DECIDE NOT TO GET THE PFIZER-BIONTECH COVID-19 VACCINE?
It is your choice to receive or not receive the Pfizer-BioNTech COVID-19 Vaccine. Should you decide not to receive it, it will not change your standard medical care.

ARE OTHER CHOICES AVAILABLE FOR PREVENTING COVID-19 BESIDES PFIZER-BIONTECH COVID-19 VACCINE?
Currently, there is no approved alternative vaccine available for prevention of COVID-19. Other vaccines to prevent COVID-19 may be available under Emergency Use Authorization.

CAN I RECEIVE THE PFIZER-BIONTECH COVID-19 VACCINE WITH OTHER VACCINES?
There is no information on the use of the Pfizer-BioNTech COVID-19 Vaccine with other vaccines.

WHAT IF I AM PREGNANT OR BREASTFEEDING?
If you are pregnant or breastfeeding, discuss your options with your healthcare provider.

WILL THE PFIZER-BIONTECH COVID-19 VACCINE GIVE ME COVID-19?

No. The Pfizer-BioNTech COVID-19 Vaccine does not contain SARS-CoV-2 and cannot give you COVID-19.

KEEP YOUR VACCINATION CARD
When you get your first dose, you will get a vaccination card to show you when to return for your second dose of Pfizer-BioNTech COVID-19 Vaccine. Remember to bring your card when you return.

ADDITIONAL INFORMATION
If you have questions, visit the website or call the telephone number provided below.

To access the most recent Fact Sheets, please scan the QR code provided below.

Global website	Telephone number
www.cvdvaccine.com	1-877-829-2619 (1-877-VAX-CO19)

HOW CAN I LEARN MORE?
- Ask the vaccination provider.
- Visit CDC at https://www.cdc.gov/coronavirus/2019-ncov/index.html.
- Visit FDA at https://www.fda.gov/emergency-preparedness-and-response/mcm-legal-regulatory-and-policy-framework/emergency-use-authorization.
- Contact your local or state public health department.

WHERE WILL MY VACCINATION INFORMATION BE RECORDED?
The vaccination provider may include your vaccination information in your state/local jurisdiction's Immunization Information System (IIS) or other designated system. This will ensure that you receive the same vaccine when you return for the second dose. For more information about IISs visit: https://www.cdc.gov/vaccines/programs/iis/about.html.

WHAT IS THE COUNTERMEASURES INJURY COMPENSATION PROGRAM?
The Countermeasures Injury Compensation Program (CICP) is a federal program that may help pay for costs of medical care and other specific expenses of certain people who have been seriously injured by certain medicines or vaccines, including this vaccine. Generally, a claim must be submitted to the CICP within one (1) year from the date of receiving the vaccine. To learn more about this program, visit www.hrsa.gov/cicp/ or call 1-855-266-2427.

WHAT IS AN EMERGENCY USE AUTHORIZATION (EUA)?

The United States FDA has made the Pfizer-BioNTech COVID-19 Vaccine available under an emergency access mechanism called an EUA. The EUA is supported by a Secretary of Health and Human Services (HHS) declaration that circumstances exist to justify the emergency use of drugs and biological products during the COVID-19 pandemic.

The Pfizer-BioNTech COVID-19 Vaccine has not undergone the same type of review as an FDA-approved or cleared product. FDA may issue an EUA when certain criteria are met, which includes that there are no adequate, approved, available alternatives. In addition, the FDA decision is based on the totality of scientific evidence available showing that the product may be effective to prevent COVID-19 during the COVID-19 pandemic and that the known and potential benefits of the product outweigh the known and potential risks of the product. All of these criteria must be met to allow for the product to be used in the treatment of patients during the COVID-19 pandemic.

The EUA for the Pfizer-BioNTech COVID-19 Vaccine is in effect for the duration of the COVID-19 EUA declaration justifying emergency use of these products, unless terminated or revoked (after which the products may no longer be used).

Manufactured by
Pfizer Inc., New York, NY 10017

Manufactured for
BioNTech Manufacturing GmbH An der Goldgrube 12
55131 Mainz, Germany

LAB-1451-1.1

Revised: December 2020

FACT SHEET FOR RECIPIENTS AND CAREGIVERS

EMERGENCY USE AUTHORIZATION (EUA) OF THE MODERNA COVID-19 VACCINE TO PREVENT CORONAVIRUS DISEASE 2019 (COVID-19) IN INDIVIDUALS 18 YEARS OF AGE AND OLDER

You are being offered the Moderna COVID-19 Vaccine to prevent Coronavirus Disease 2019 (COVID-19) caused by SARS-CoV-2. This Fact Sheet contains information to help you understand the risks and benefits of the Moderna COVID-19 Vaccine, which you may receive because there is currently a pandemic of COVID-19.

The Moderna COVID-19 Vaccine is a vaccine and may prevent you from getting COVID-19. There is no U.S. Food and Drug Administration (FDA) approved vaccine to prevent COVID-19.

Read this Fact Sheet for information about the Moderna COVID-19 Vaccine. Talk to the vaccination provider if you have questions. It is your choice to receive the Moderna COVID-19 Vaccine.

The Moderna COVID-19 Vaccine is administered as a 2-dose series, 1 month apart, into the muscle.

The Moderna COVID-19 Vaccine may not protect everyone.

This Fact Sheet may have been updated. For the most recent Fact Sheet, please visit www.modernatx.com/covid19vaccine-eua.

WHAT YOU NEED TO KNOW BEFORE YOU GET THIS VACCINE

WHAT IS COVID-19?

COVID-19 is caused by a coronavirus called SARS-CoV-2. This type of coronavirus has not been seen before. You can get COVID-19 through contact with another person who has the virus. It is predominantly a respiratory illness that can affect other organs. People with COVID-19 have had a wide range of symptoms reported, ranging from mild symptoms to severe illness. Symptoms may appear 2 to 14 days after exposure to the virus. Symptoms may include: fever or chills; cough; shortness of breath; fatigue; muscle or body aches; headache; new loss of taste or smell; sore throat; congestion or runny nose; nausea or vomiting; diarrhea.

WHAT IS THE MODERNA COVID-19 VACCINE?

The Moderna COVID-19 Vaccine is an unapproved vaccine that may prevent COVID-19. There is no FDA-approved vaccine to prevent COVID-19.

The FDA has authorized the emergency use of the Moderna COVID-19 Vaccine to prevent COVID-19 in individuals 18 years of age and older under an Emergency Use Authorization (EUA).

For more information on EUA, see the "**What is an Emergency Use Authorization (EUA)?**" section at the end of this Fact Sheet.

WHAT SHOULD YOU MENTION TO YOUR VACCINATION PROVIDER BEFORE YOU GET THE MODERNA COVID-19 VACCINE?

Tell your vaccination provider about all of your medical conditions, including if you:

- have any allergies
- have a fever
- have a bleeding disorder or are on a blood thinner
- are immunocompromised or are on a medicine that affects your immune system
- are pregnant or plan to become pregnant
- are breastfeeding
- have received another COVID-19 vaccine

WHO SHOULD GET THE MODERNA COVID-19 VACCINE?

FDA has authorized the emergency use of the Moderna COVID-19 Vaccine in individuals 18 years of age and older.

WHO SHOULD NOT GET THE MODERNA COVID-19 VACCINE?

You should not get the Moderna COVID-19 Vaccine if you:

- had a severe allergic reaction after a previous dose of this vaccine
- had a severe allergic reaction to any ingredient of this vaccine

WHAT ARE THE INGREDIENTS IN THE MODERNA COVID-19 VACCINE?

The Moderna COVID-19 Vaccine contains the following ingredients: messenger ribonucleic acid (mRNA), lipids (SM-102, polyethylene glycol [PEG] 2000 dimyristoyl glycerol [DMG], cholesterol, and 1,2-distearoyl-sn-glycero-3-phosphocholine [DSPC]), tromethamine, tromethamine hydrochloride, acetic acid, sodium acetate, and sucrose.

HOW IS THE MODERNA COVID-19 VACCINE GIVEN?

The Moderna COVID-19 Vaccine will be given to you as an injection into the muscle.

The Moderna COVID-19 Vaccine vaccination series is 2 doses given 1 month apart.

If you receive one dose of the Moderna COVID-19 Vaccine, you should receive a second dose of the same vaccine 1 month later to complete the vaccination series.

HAS THE MODERNA COVID-19 VACCINE BEEN USED BEFORE?

The Moderna COVID-19 Vaccine is an unapproved vaccine. In clinical trials, approximately 15,400 individuals 18 years of age and older have received at least 1 dose of the Moderna COVID-19 Vaccine.

WHAT ARE THE BENEFITS OF THE MODERNA COVID-19 VACCINE?

In an ongoing clinical trial, the Moderna COVID-19 Vaccine has been shown to prevent COVID-19 following 2 doses given 1 month apart. The duration of protection against COVID-19 is currently unknown.

WHAT ARE THE RISKS OF THE MODERNA COVID-19 VACCINE?
Side effects that have been reported with the Moderna COVID-19 Vaccine include:

- Injection site reactions: pain, tenderness and swelling of the lymph nodes in the same arm of the injection, swelling (hardness), and redness
- General side effects: fatigue, headache, muscle pain, joint pain, chills, nausea and vomiting, and fever

There is a remote chance that the Moderna COVID-19 Vaccine could cause a severe allergic reaction. A severe allergic reaction would usually occur within a few minutes to one hour after getting a dose of the Moderna COVID-19 Vaccine. For this reason, your vaccination provider may ask you to stay at the place where you received your vaccine for monitoring after vaccination. Signs of a severe allergic reaction can include:

- Difficulty breathing
- Swelling of your face and throat
- A fast heartbeat
- A bad rash all over your body
- Dizziness and weakness

These may not be all the possible side effects of the Moderna COVID-19 Vaccine. Serious and unexpected side effects may occur. The Moderna COVID-19 Vaccine is still being studied in clinical trials.

WHAT SHOULD I DO ABOUT SIDE EFFECTS?
If you experience a severe allergic reaction, call 9-1-1, or go to the nearest hospital.

Call the vaccination provider or your healthcare provider if you have any side effects that bother you or do not go away.

Report vaccine side effects to **FDA/CDC Vaccine Adverse Event Reporting System (VAERS)**. The VAERS toll-free number is 1-800-822-7967 or report online to https://vaers.hhs.gov/reportevent.html. Please include "Moderna COVID-19 Vaccine EUA" in the first line of box #18 of the report form.

In addition, you can report side effects to ModernaTX, Inc. at 1-866-MODERNA (1-866-663-3762).

You may also be given an option to enroll in **v-safe. V-safe** is a new voluntary smartphone-based tool that uses text messaging and web surveys to check in with people who have been vaccinated to identify potential side effects after COVID-19 vaccination. **V-safe** asks questions that help CDC monitor the safety of COVID-19 vaccines. **V-safe** also provides second-dose reminders if needed and live telephone follow-up by CDC if participants report a significant health impact following COVID-19 vaccination. For more information on how to sign up, visit: www.cdc .gov/vsafe.

WHAT IF I DECIDE NOT TO GET THE MODERNA COVID-19 VACCINE?
It is your choice to receive or not receive the Moderna COVID-19 Vaccine. Should you decide not to receive it, it will not change your standard medical care.

ARE OTHER CHOICES AVAILABLE FOR PREVENTING COVID-19 BESIDES MODERNA COVID-19 VACCINE?
Currently, there is no FDA-approved alternative vaccine available for prevention of COVID-19. Other vaccines to prevent COVID-19 may be available under Emergency Use Authorization.

CAN I RECEIVE THE MODERNA COVID-19 VACCINE WITH OTHER VACCINES?
There is no information on the use of the Moderna COVID-19 Vaccine with other vaccines.

WHAT IF I AM PREGNANT OR BREASTFEEDING?
If you are pregnant or breastfeeding, discuss your options with your healthcare provider.

WILL THE MODERNA COVID-19 VACCINE GIVE ME COVID-19?
No. The Moderna COVID-19 Vaccine does not contain SARS-CoV-2 and cannot give you COVID-19.

KEEP YOUR VACCINATION CARD
When you receive your first dose, you will get a vaccination card to show you when to return for your second dose of the Moderna COVID-19 Vaccine. Remember to bring your card when you return.

ADDITIONAL INFORMATION
If you have questions, visit the website or call the telephone number provided below.

To access the most recent Fact Sheets, please scan the QR code provided below.

Moderna COVID-19 Vaccine website	Telephone number
www.modernatx.com/covid19vaccine-eua	1-866-MODERNA (1-866-663-3762)

HOW CAN I LEARN MORE?
- Ask the vaccination provider
- Visit CDC at https://www.cdc.gov/coronavirus/2019-ncov/index.html
- Visit FDA at https://www.fda.gov/emergency-preparedness-and-response/mcm-legal-regulatory-and-policy-framework/emergency-use-authorization
- Contact your state or local public health department

WHERE WILL MY VACCINATION INFORMATION BE RECORDED?
The vaccination provider may include your vaccination information in your state/local jurisdiction's Immunization Information System (IIS) or other designated system. This will ensure that you receive the same vaccine when you return for the second dose. For more information about IISs, visit: https://www.cdc.gov/vaccines/programs/iis/about.html.

WHAT IS THE COUNTERMEASURES INJURY COMPENSATION PROGRAM?
The Countermeasures Injury Compensation Program (CICP) is a federal program that may help pay for costs of medical care and other specific expenses of certain people who have been seriously injured by certain medicines or vaccines, including this vaccine. Generally, a claim must be submitted to the CICP within one (1) year from the date of receiving the vaccine. To learn more about this program, visit www.hrsa.gov/cicp/ or call 1-855-266-2427.

WHAT IS AN EMERGENCY USE AUTHORIZATION (EUA)?
The United States FDA has made the Moderna COVID-19 Vaccine available under an emergency access mechanism called an EUA. The EUA is supported by a Secretary of Health and Human Services (HHS) declaration that circumstances exist to justify the emergency use of drugs and biological products during the COVID-19 pandemic.

The Moderna COVID-19 Vaccine has not undergone the same type of review as an FDA-approved or cleared product. FDA may issue an EUA when certain criteria are met, which includes that there are no adequate, approved, and available alternatives. In addition, the FDA decision is based on the totality of the scientific evidence available showing that the product may be effective to prevent COVID-19 during the COVID-19 pandemic and that the known and potential benefits of the product outweigh the known and potential risks of the product. All of these criteria must be met to allow for the product to be used during the COVID-19 pandemic.

The EUA for the Moderna COVID-19 Vaccine is in effect for the duration of the COVID-19 EUA declaration justifying emergency use of these products, unless terminated or revoked (after which the products may no longer be used).

©2020 ModernaTX, Inc. All rights reserved. Patent(s): www.modernatx.com/patents Revised: 12/2020

FACT SHEET FOR RECIPIENTS AND CAREGIVERS EMERGENCY USE AUTHORIZATION (EUA) OF THE JANSSEN COVID-19 VACCINE TO PREVENT CORONAVIRUS DISEASE 2019 (COVID-19) IN INDIVIDUALS 18 YEARS OF AGE AND OLDER You are being offered the Janssen COVID-19 Vaccine to prevent Coronavirus Disease 2019 (COVID-19) caused by SARS-CoV-2. This Fact Sheet contains information to help you understand the risks and benefits of receiving the Janssen COVID-19 Vaccine, which you may receive because there is currently a pandemic of COVID-19. The Janssen COVID-19 Vaccine may prevent you from getting COVID-19. There is no U.S. Food and Drug Administration (FDA) approved vaccine to prevent COVID-19. Read this Fact Sheet for information about the Janssen COVID-19 Vaccine. Talk to the vaccination provider if you have questions. It is your choice to receive the Janssen COVID-19 Vaccine. The Janssen COVID-19 Vaccine is administered as a single dose, into the muscle. The Janssen COVID-19 Vaccine may not protect everyone. This Fact Sheet may have been updated. For the most recent Fact Sheet, please visit www.janssencovid19vaccine.com. WHAT YOU NEED TO KNOW BEFORE YOU GET THIS VACCINE WHAT IS COVID-19? COVID-19 is caused by a coronavirus called SARS-CoV-2. This type of coronavirus has not been seen before. You can get COVID-19 through contact with another person who has the virus. It is predominantly a respiratory illness that can affect other organs. People with COVID-19 have had a wide range of symptoms reported, ranging from mild symptoms to severe illness. Symptoms may appear 2 to 14 days after exposure to the virus. Common symptoms may include: fever or chills; cough; shortness of breath; fatigue; muscle or body aches; headache; new loss of taste or smell; sore throat; congestion or runny nose; nausea or vomiting; diarrhea. WHAT IS THE JANSSEN COVID-19 VACCINE? The Janssen COVID-19 Vaccine is an unapproved vaccine that may prevent COVID-19. There is no FDA-approved vaccine to prevent COVID-19. The FDA has authorized the emergency use of the Janssen COVID-19 Vaccine to prevent COVID-19 in individuals 18 years of age and older under an Emergency Use Authorization (EUA). For more information on EUA, see the “What is an Emergency Use Authorization (EUA)?” section at the end of this Fact Sheet.

WHAT SHOULD YOU MENTION TO YOUR VACCINATION PROVIDER BEFORE YOU GET THE JANSSEN COVID-19 VACCINE? Tell the vaccination provider about all of your medical conditions, including if you:

• have any allergies, • have a fever, • have a bleeding disorder or are on a blood thinner, • are immunocompromised or are on a medicine that affects your immune system, • are pregnant or plan to become pregnant, • are breastfeeding, • have received another COVID-19 vaccine, WHO SHOULD GET THE JANSSEN COVID-19 VACCINE? FDA has authorized the emergency use of the Janssen COVID-19 Vaccine in individuals 18 years of age and older. WHO SHOULD NOT GET THE JANSSEN COVID-19 VACCINE? You should not get the Janssen COVID-19 Vaccine if you:

• had a severe allergic reaction to any ingredient of this vaccine. WHAT ARE THE INGREDIENTS IN THE JANSSEN COVID-19 VACCINE? The Janssen COVID-19 Vaccine includes the following ingredients: recombinant, replication-incompetent adenovirus type 26 expressing the SARS-CoV-2 spike protein, citric acid monohydrate, trisodium citrate dihydrate, ethanol, 2-hydroxypropyl-β-cyclodextrin (HBCD), polysorbate-80, sodium chloride. HOW IS THE JANSSEN COVID -19 VACCINE GIVEN? The Janssen COVID-19 Vaccine will be given to you as an injection into the muscle. The Janssen COVID-19 Vaccine vaccination schedule is a single dose. HAS THE JANSSEN COVID-19 VACCINE BEEN USED BEFORE? The Janssen

COVID-19 Vaccine is an unapproved vaccine. In an ongoing clinical trial, 21,895 individuals 18 years of age and older have received the Janssen COVID-19 Vaccine.
3
WHAT ARE THE BENEFITS OF THE JANSSEN COVID-19 VACCINE? In an ongoing clinical trial, the Janssen COVID-19 Vaccine has been shown to prevent COVID-19 following a single dose. The duration of protection against COVID-19 is currently unknown. WHAT ARE THE RISKS OF THE JANSSEN COVID-19 VACCINE? Side effects that have been reported with the Janssen COVID-19 Vaccine include:
• Injection site reactions: pain, redness of the skin and swelling. • General side effects: headache, feeling very tired, muscle aches, nausea, and fever. There is a remote chance that the Janssen COVID-19 Vaccine could cause a severe allergic reaction. A severe allergic reaction would usually occur within a few minutes to one hour after getting a dose of the Janssen COVID-19 Vaccine. For this reason, your vaccination provider may ask you to stay at the place where you received your vaccine for monitoring after vaccination. Signs of a severe allergic reaction can include:
• Difficulty breathing, • Swelling of your face and throat, • A fast heartbeat, • A bad rash all over your body, • Dizziness and weakness. Blood clots involving blood vessels in the brain, abdomen, and legs along with low levels of platelets (blood cells that help your body stop bleeding), have occurred in some people who have received the Janssen COVID-19 Vaccine. In people who developed these blood clots and low levels of platelets, symptoms began approximately one to two-weeks following vaccination. Most people who developed these blood clots and low levels of platelets were females ages 18 through 49 years. The chance of having this occur is remote. You should seek medical attention right away if you have any of the following symptoms after receiving Janssen COVID-19 Vaccine:
• Shortness of breath, • Chest pain, • Leg swelling, • Persistent abdominal pain, • Severe or persistent headaches or blurred vision, • Easy bruising or tiny blood spots under the skin beyond the site of the injection.
4
These may not be all the possible side effects of the Janssen COVID-19 Vaccine. Serious and unexpected effects may occur. The Janssen COVID-19 Vaccine is still being studied in clinical trials. WHAT SHOULD I DO ABOUT SIDE EFFECTS? If you experience a severe allergic reaction, call 9-1-1, or go to the nearest hospital. Call the vaccination provider or your healthcare provider if you have any side effects that bother you or do not go away. Report vaccine side effects to FDA/CDC Vaccine Adverse Event Reporting System (VAERS). The VAERS toll-free number is 1-800-822-7967 or report online to https://vaers.hhs.gov/reportevent.html. Please include “Janssen COVID-19 Vaccine EUA” in the first line of box #18 of the report form. In addition, you can report side effects to Janssen Biotech, Inc. at the contact information provided below. e-mail Fax number Telephone numbers JNJvaccineAE@its.jnj.com 215-293-9955 US Toll Free: 1-800-565-4008 US Toll: (908) 455-9922

You may also be given an option to enroll in v-safe. V-safe is a new voluntary smartphone-based tool that uses text messaging and web surveys to check in with people who have been vaccinated to identify potential side effects after COVID-19 vaccination. V-safe asks questions that help CDC monitor the safety of COVID-19 vaccines. V-safe also provides live telephone follow-up by CDC if participants report a significant health impact following COVID-19 vaccination. For more information on how to sign up, visit: www.cdc.gov/vsafe. WHAT IF I DECIDE NOT TO GET THE JANSSEN COVID-19 VACCINE? It is your choice to receive or not receive the

Janssen COVID-19 Vaccine. Should you decide not to receive it, it will not change your standard medical care. ARE OTHER CHOICES AVAILABLE FOR PREVENTING COVID-19 BESIDES JANSSEN COVID-19 VACCINE? Currently, there is no FDA approved alternative vaccine available for prevention of COVID-19. Other vaccines to prevent COVID-19 may be available under Emergency Use Authorization. CAN I RECEIVE THE JANSSEN COVID-19 VACCINE WITH OTHER VACCINES? There is no information on the use of the Janssen COVID-19 Vaccine with other vaccines.

WHAT IF I AM PREGNANT OR BREASTFEEDING? If you are pregnant or breastfeeding, discuss your options with your healthcare provider. WILL THE JANSSEN COVID-19 VACCINE GIVE ME COVID-19? No. The Janssen COVID-19 Vaccine does not contain SARS-CoV-2 and cannot give you COVID-19. KEEP YOUR VACCINATION CARD When you receive the Janssen COVID-19 Vaccine, you will get a vaccination card to document the name of the vaccine and date of when you received the vaccine. ADDITIONAL INFORMATION If you have questions or to access the most recent Janssen COVID-19 Vaccine Fact Sheets, scan the QR code using your device, visit the website or call the telephone numbers provided below. QR Code Fact Sheets Website Telephone numbers

www.janssencovid19vaccine.com. US Toll Free: 1-800-565-4008 US Toll: (908) 455-9922

HOW CAN I LEARN MORE?

• Ask the vaccination provider. • Visit CDC at https://www.cdc.gov/coronavirus/2019-ncov/index.html. • Visit FDA at https://www.fda.gov/emergency-preparedness-and-response/mcm-legalregulatory-and-policy-framework/emergency-use-authorization. Contact your local or state public health department. WHERE WILL MY VACCINATION INFORMATION BE RECORDED? The vaccination provider may include your vaccination information in your state/local jurisdiction's Immunization Information System (IIS) or other designated system. For more information about IISs visit: https://www.cdc.gov/vaccines/programs/iis/about.html.

CAN I BE CHARGED AN ADMINISTRATION FEE FOR RECEIPT OF THE COVID-19 VACCINE? No. At this time, the provider cannot charge you for a vaccine dose and you cannot be charged an out-of-pocket vaccine administration fee or any other fee if only receiving a COVID-19 vaccination. However, vaccination providers may seek appropriate reimbursement from a program or plan that covers COVID-19 vaccine administration fees for the vaccine recipient (private insurance, Medicare, Medicaid, HRSA COVID-19 Uninsured Program for non-insured recipients). WHERE CAN I REPORT CASES OF SUSPECTED FRAUD? Individuals becoming aware of any potential violations of the CDC COVID-19 Vaccination Program requirements are encouraged to report them to the Office of the Inspector General, U.S. Department of Health and Human Services, at 1-800-HHS-TIPS or TIPS.HHS.GOV. WHAT IS THE COUNTERMEASURE INJURY COMPENSATION PROGRAM? The Countermeasures Injury Compensation Program (CICP) is a federal program that may help pay for costs of medical care and other specific expenses for certain people who have been seriously injured by certain medicines or vaccines, including this vaccine. Generally, a claim must be submitted to the CICP within one (1) year from the date of receiving the vaccine. To learn more about this program, visit www.hrsa.gov/cicp or call 1-855-266-2427. WHAT IS AN EMERGENCY USE AUTHORIZATION (EUA)? The United States FDA has made the Janssen COVID-19 Vaccine

available under an emergency access mechanism called an EUA. The EUA is supported by a Secretary of Health and Human Services (HHS) declaration that circumstances exist to justify the emergency use of drugs and biological products during the COVID-19 pandemic. The Janssen COVID-19 Vaccine has not undergone the same type of review as an FDA-approved or cleared product. FDA may issue an EUA when certain criteria are met, which includes that there are no adequate, approved, and available alternatives. In addition, the FDA decision is based on the totality of scientific evidence available showing that the product may be effective to prevent COVID-19 during the COVID-19 pandemic and that the known and potential benefits of the product outweigh the known and potential risks of the product. All of these criteria must be met to allow for the product to be used during the COVID-19 pandemic. The EUA for the Janssen COVID-19 Vaccine is in effect for the duration of the COVID-19 declaration justifying emergency use of these products, unless terminated or revoked (after which the products may no longer be used).

Manufactured by: Janssen Biotech, Inc. a Janssen Pharmaceutical Company of Johnson & Johnson Horsham, PA 19044, USA

7

© 2021 Janssen Pharmaceutical Companies

For more information, call US Toll Free: 1-800-565-4008, US Toll: (908) 455-9922 or go to www.janssencovid19vaccine.com

Revised: Apr/23/2021